Rocket Pharmaceuticals, Inc. financial data

Symbol
RCKT, RCKTW on Nasdaq
Industry
Pharmaceutical Preparations
Location
350 Fifth Avenue, Suite 7530, New York, New York
State of incorporation
Delaware
Fiscal year end
December 31
Former names
INOTEK PHARMACEUTICALS CORP (to 12/22/2017)
Latest financial report
Q1 2024 - May 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 993 % -7.42%
Debt-to-equity 13.2 % +6.1%
Return On Equity -53.1 % +4.67%
Return On Assets -46.9 % +5.31%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 90.8 M shares +12.8%
Common Stock, Shares, Outstanding 90.6 M shares +12.7%
Entity Public Float 1.2 B USD +86.2%
Common Stock, Value, Issued 906 K USD +12.7%
Weighted Average Number of Shares Outstanding, Basic 93.5 M shares +17.7%
Weighted Average Number of Shares Outstanding, Diluted 93.5 M shares +17.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 185 M USD +2.24%
General and Administrative Expense 79.6 M USD +26.8%
Operating Income (Loss) -265 M USD -8.55%
Nonoperating Income (Expense) 2.48 M USD
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -249 M USD -5.1%
Earnings Per Share, Basic -2.85 USD/shares +14.2%
Earnings Per Share, Diluted -2.85 USD/shares +14.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 35.3 M USD -45.4%
Cash, Cash Equivalents, and Short-term Investments 330 M USD -8.25%
Assets, Current 345 M USD +2.11%
Property, Plant and Equipment, Net 39.3 M USD +28.6%
Operating Lease, Right-of-Use Asset 4.77 M USD +2284%
Intangible Assets, Net (Excluding Goodwill) 25.2 M USD -2.23%
Goodwill 39.2 M USD 0%
Assets 499 M USD -2.98%
Employee-related Liabilities, Current 4.19 M USD -0.17%
Liabilities, Current 33 M USD +5.61%
Operating Lease, Liability, Noncurrent 3.71 M USD +1757%
Other Liabilities, Noncurrent 1.91 M USD +1.65%
Liabilities 57.9 M USD +3.69%
Accumulated Other Comprehensive Income (Loss), Net of Tax -135 K USD -50%
Retained Earnings (Accumulated Deficit) -1.02 B USD -32.3%
Stockholders' Equity Attributable to Parent 442 M USD -3.79%
Liabilities and Equity 499 M USD -2.98%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -56.9 M USD +1.22%
Net Cash Provided by (Used in) Financing Activities 1.18 M USD -93.5%
Net Cash Provided by (Used in) Investing Activities 35 M USD
Common Stock, Shares Authorized 120 M shares 0%
Common Stock, Shares, Issued 90.6 M shares +12.7%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 36.6 M USD -44.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 108 M USD +18.9%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Operating Lease, Liability 4.78 M USD +9.71%
Payments to Acquire Property, Plant, and Equipment 2.04 M USD -32.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -249 M USD -5.36%
Lessee, Operating Lease, Liability, to be Paid 6.52 M USD +5.24%
Property, Plant and Equipment, Gross 55.1 M USD +35%
Operating Lease, Liability, Current 1.06 M USD +25.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.01 M USD +86.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 1 M USD +25.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure +12.4%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.74 M USD -5.32%
Lessee, Operating Lease, Liability, to be Paid, Year Three 759 K USD +39.3%
Deferred Tax Assets, Operating Loss Carryforwards 45.3 M USD +34.4%
Preferred Stock, Shares Authorized 5 M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 522 K USD +3.16%
Operating Lease, Payments 333 K USD +27.6%
Additional Paid in Capital 1.46 B USD +18.8%
Depreciation, Depletion and Amortization 1.7 M USD +54.5%
Share-based Payment Arrangement, Expense 40.7 M USD +21.1%
Interest Expense 1.88 M USD +0.64%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%